FDA Peptide Regulation in 2026: What Providers Need to Know

A Regulatory Inflection Point

The regulatory environment for compounded peptides has undergone its most significant transformation in a decade. Between 2023 and 2026, the FDA has taken a series of actions that have reshaped which peptides can be compounded, by whom, and under what conditions. For providers who prescribe peptide therapies, understanding this evolving landscape is not optional — it is a matter of legal compliance and patient safety.

The 503A and 503B Framework

The foundation of peptide compounding regulation rests on Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Quality and Security Act (DQSA) of 2013:

503A pharmacies are traditional compounding pharmacies that prepare medications pursuant to individual patient prescriptions. They must be licensed by their state board of pharmacy, comply with USP standards, and use ingredients that are either components of FDA-approved drugs or listed on the FDA's Bulk Drug Substances list. 503A pharmacies are exempt from FDA's current Good Manufacturing Practice (cGMP) requirements and pre-market approval, provided they meet specific conditions.

503B outsourcing facilities are registered with the FDA, inspected on a risk-based schedule, and must comply with cGMP requirements. They can compound without individual prescriptions ("office use" or "anticipatory compounding"), making them the primary source for clinics that stock peptides for in-office administration. 503B facilities are subject to more rigorous quality standards, including environmental monitoring, stability testing, and comprehensive batch testing.

The Bulk Drug Substances List: What Can Be Compounded

The FDA maintains lists of bulk drug substances that can be used in compounding. For peptides, the critical question is whether a specific peptide appears on these lists or qualifies under other exemptions. The FDA has been actively reviewing peptide nominations for the 503B Bulks list, with several rounds of public comment and expert panel reviews.

As of early 2026, the landscape includes:

Peptides with clear compounding pathways: Certain peptides have been nominated, reviewed, and accepted onto the 503B Bulks list or qualify as components of FDA-approved drugs. These include several well-established compounds used in endocrinology and reproductive medicine.

Peptides in regulatory limbo: Several popular peptides in the functional medicine space are under active FDA review. Their compounding status may change based on ongoing evaluations of clinical need, safety, and whether an FDA-approved equivalent exists.

Peptides the FDA has explicitly restricted: The FDA has issued warning letters and taken enforcement actions against compounding pharmacies producing certain peptides that do not meet the criteria for lawful compounding. Providers prescribing these peptides face potential legal exposure.

The Semaglutide Compounding Controversy

The compounding of semaglutide has been the highest-profile regulatory issue in the peptide space. During the semaglutide shortage (2022-2024), the FDA's drug shortage provisions allowed compounding pharmacies to produce copies of semaglutide. As supply has stabilized, the FDA has moved to end this allowance, leading to significant controversy and litigation.

Key points for providers:

• The FDA's position is that semaglutide should not be compounded when the commercially manufactured product is available in adequate supply.
• Several compounding pharmacies and industry groups have challenged FDA enforcement actions in court.
• Providers should verify the current status of semaglutide compounding in their jurisdiction before prescribing compounded versions.
• Prescribing a compounded version of an available FDA-approved drug may expose providers to liability risk.

State-Level Variation

Adding complexity, individual states have varying regulations on compounding that may be more or less restrictive than federal rules. Some states have enacted their own legislation regarding peptide compounding, telehealth prescribing of peptides, and pharmacy oversight. Providers should be familiar with both federal and state regulations applicable to their practice location and their patients' locations (particularly relevant for telehealth practices).

What Providers Should Do Now

1. Audit your peptide sourcing: Confirm that every peptide you prescribe comes from a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility. Verify their registration status, inspection history, and quality certifications. The FDA maintains a searchable database of registered 503B facilities.

2. Stay current on the Bulks list: Monitor FDA Federal Register notices and the Peptide Association's regulatory updates for changes to the compounding status of specific peptides. What was compoundable last year may not be today.

3. Document medical necessity: For peptides used off-label or in clinical contexts where the evidence base is still developing, thorough documentation of medical necessity, informed consent, and clinical rationale is essential for both patient safety and legal protection.

4. Understand the difference between "not FDA-approved" and "illegal": Off-label prescribing of legally compounded substances is a well-established practice in medicine. However, prescribing substances that cannot be lawfully compounded under either 503A or 503B frameworks is a different matter. The distinction is critical.

5. Engage with the regulatory process: The FDA accepts public comments on proposed rules and nominations for the Bulks list. Provider organizations, including the Peptide Association, can and should participate in this process to ensure that the regulatory framework reflects clinical reality and patient needs.

Looking Ahead

The regulatory trajectory is toward greater oversight, not less. This is not inherently negative — quality standards protect patients, and a clear regulatory framework benefits reputable providers and pharmacies. The challenge is ensuring that regulation is evidence-based and does not unnecessarily restrict access to therapeutically valuable peptides that lack commercial sponsors willing to fund the full FDA approval process. The Peptide Association is actively engaged in this process on behalf of our provider and patient communities.